Sanfilippo syndrome

Mendelian MONDO:0018937 Pathograph 29 Mucopolysaccharidosis Lysosomal Storage Disorders Neurodegeneration

Sanfilippo syndrome, also called mucopolysaccharidosis type III (MPS III), is an autosomal recessive lysosomal storage disorder caused by deficiency of one of four enzymes required for heparan sulfate catabolism. The shared disease mechanism is failed lysosomal degradation of heparan sulfate, followed by heparan sulfate storage, neuroinflammation, cortical synaptic dysfunction, and progressive central nervous system degeneration. Clinically, the syndrome is dominated by progressive intellectual disability, developmental regression, autism-spectrum and other behavioral manifestations, hyperactivity, and sleep disturbance. Systemic involvement is comparatively mild relative to other mucopolysaccharidoses but can include musculoskeletal, hearing, respiratory, and cardiac manifestations.

Ask OpenScientist

Ask a research question about Sanfilippo syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
6
Pathophys.
16
Phenotypes
29
Pathograph
3
Treatments
4
Subtypes
1
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0018937 mucopolysaccharidosis type 3
skos:exactMatch MONDO
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
All four Sanfilippo subtypes are inherited as autosomal recessive disorders.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"MPS III is inherited in an autosomal recessive manner."
GeneReviews explicitly states that the Sanfilippo syndrome spectrum is inherited in an autosomal recessive manner.
◆

Subtypes

4
Sanfilippo syndrome type A (MPS IIIA) MONDO:0009655
SGSH link
SGSH-related Sanfilippo syndrome caused by sulfamidase deficiency.
Show evidence (2 references)
PMID:31536183 SUPPORT Human Clinical
"biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified"
The GeneReviews reference for MPS III identifies SGSH as one of the four causative genes for MPS III, with the MPS IIIA subtype specifically caused by biallelic pathogenic variants in SGSH (sulfamidase deficiency).
CGGV:assertion_438dab6d-abf4-44e8-a176-bb39ae128052-2022-06-15T160000.000Z SUPPORT Other
"SGSH | HGNC:10818 | mucopolysaccharidosis type 3A | MONDO:0009655 | AR | Definitive"
ClinGen's Lysosomal Diseases GCEP classifies the SGSH-MPS IIIA gene-disease relationship as Definitive with autosomal recessive inheritance.
Sanfilippo syndrome type B (MPS IIIB) MONDO:0009656
NAGLU link
NAGLU-related Sanfilippo syndrome caused by alpha-N-acetylglucosaminidase deficiency.
Show evidence (2 references)
PMID:31536183 SUPPORT Human Clinical
"biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified"
The GeneReviews reference for MPS III identifies NAGLU as one of the four causative genes for MPS III, with the MPS IIIB subtype specifically caused by biallelic pathogenic variants in NAGLU (alpha-N-acetylglucosaminidase deficiency).
CGGV:assertion_7ee5629a-f6c2-4187-a802-d570f7180478-2022-08-22T160000.000Z SUPPORT Other
"NAGLU | HGNC:7632 | mucopolysaccharidosis type 3B | MONDO:0009656 | AR | Definitive"
ClinGen's Lysosomal Diseases GCEP classifies the NAGLU-MPS IIIB gene-disease relationship as Definitive with autosomal recessive inheritance.
Sanfilippo syndrome type C (MPS IIIC) MONDO:0009657
HGSNAT link
HGSNAT-related Sanfilippo syndrome caused by heparan-alpha-glucosaminide N-acetyltransferase deficiency.
Show evidence (2 references)
PMID:31536183 SUPPORT Human Clinical
"biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified"
The GeneReviews reference for MPS III identifies HGSNAT as one of the four causative genes for MPS III, with the MPS IIIC subtype specifically caused by biallelic pathogenic variants in HGSNAT (heparan-alpha-glucosaminide N-acetyltransferase deficiency).
CGGV:assertion_943b7a75-eb7f-415b-ba80-de6b09cc5a43-2023-12-04T170000.000Z SUPPORT Other
"HGSNAT | HGNC:26527 | mucopolysaccharidosis type 3C | MONDO:0009657 | AR | Definitive"
ClinGen's Lysosomal Diseases GCEP classifies the HGSNAT-MPS IIIC gene-disease relationship as Definitive with autosomal recessive inheritance.
Sanfilippo syndrome type D (MPS IIID) MONDO:0009658
GNS link
GNS-related Sanfilippo syndrome caused by N-acetylglucosamine-6-sulfatase deficiency.
Show evidence (2 references)
PMID:31536183 SUPPORT Human Clinical
"biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified"
The GeneReviews reference for MPS III identifies GNS as one of the four causative genes for MPS III, with the MPS IIID subtype specifically caused by biallelic pathogenic variants in GNS (N-acetylglucosamine-6-sulfatase deficiency).
CGGV:assertion_63312833-baef-4b11-9769-c93957decef6-2022-09-02T160000.000Z SUPPORT Other
"GNS | HGNC:4422 | mucopolysaccharidosis type 3D | MONDO:0009658 | AR | Definitive"
ClinGen's Lysosomal Diseases GCEP classifies the GNS-MPS IIID gene-disease relationship as Definitive with autosomal recessive inheritance.
⚙

Pathophysiology

6
Lysosomal heparan sulfate catabolism defect
The root disease mechanism is deficiency of one of four lysosomal enzymes required for the stepwise degradation of heparan sulfate.
SGSH link NAGLU link HGSNAT link GNS link
heparan sulfate catabolism link ↓ DECREASED
N-sulfoglucosamine sulfohydrolase activity link ↓ DECREASED alpha-N-acetylglucosaminidase activity link ↓ DECREASED heparan-alpha-glucosaminide N-acetyltransferase activity link ↓ DECREASED N-acetylglucosamine-6-sulfatase activity link ↓ DECREASED
lysosome link
Downstream
Lysosomal heparan sulfate accumulation Failed lysosomal catabolism leads to storage of partially degraded heparan sulfate.
Subtype-specific lysosomal enzyme activity The same upstream enzymatic lesion is detected diagnostically as decreased activity of the subtype-specific lysosomal enzyme.
Show evidence (2 references)
PMID:25851924 SUPPORT Other
"Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) is a lysosomal storage disorder, caused by a deficiency in one of the four enzymes involved in the catabolism of glycosaminoglycan heparan sulfate."
This review supports a shared root mechanism upstream of the four Sanfilippo subtypes: failure of lysosomal heparan sulfate catabolism.
PMID:31536183 SUPPORT Other
"The diagnosis of MPS III is established in a proband with suggestive clinical and laboratory findings in whom either biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified."
GeneReviews confirms that the shared root disorder is genetically split across four subtype-defining lysosomal enzyme genes.
Lysosomal heparan sulfate accumulation
Partially degraded heparan sulfate accumulates within lysosomes and becomes the biochemical lesion that drives downstream brain pathology.
lysosome link
Downstream
Neuroinflammatory cascade Heparan sulfate storage triggers a neuroinflammatory response in the brain.
Cortical synaptic dysfunction Heparan sulfate oligosaccharides perturb synaptic vesicle protein homeostasis in cortical neurons.
Systemic manifestations of glycosaminoglycan storage Lysosomal heparan sulfate storage also has extraneural systemic effects, including musculoskeletal, hearing, respiratory, and cardiac involvement.
Heparan sulfate Increased heparan sulfate reports the stored substrate in Sanfilippo syndrome.
Urinary glycosaminoglycans Quantitative urinary glycosaminoglycan analysis is used as a diagnostic readout of Sanfilippo glycosaminoglycan storage.
GM2 ganglioside storage GM2 ganglioside storage is a secondary biochemical abnormality in neurodegenerative MPS III brain pathology.
Show evidence (1 reference)
PMID:36306823 SUPPORT Model Organism
"Enzyme deficiency results in accumulation of partially degraded HS within lysosomes throughout the body, leading to a progressive severe neurological disease."
This preclinical abstract directly supports lysosomal heparan sulfate storage as the immediate consequence of enzyme deficiency.
Neuroinflammatory cascade
Brain heparan sulfate storage is accompanied by microglial, astrocytic, and cytokine evidence of neuroinflammation.
microglial cell link astrocyte link
neuroinflammatory response link
brain link
Downstream
Progressive central neurodegeneration The inflammatory cascade is part of the progressive brain pathology that culminates in severe neurologic decline.
Show evidence (1 reference)
PMID:22558223 SUPPORT Model Organism
"Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary..."
IIIA and IIIB mouse models both show explicit neuroinflammatory brain pathology alongside lysosomal storage.
Cortical synaptic dysfunction
Sanfilippo syndrome includes early cortical synaptic dysfunction with abnormal synaptic vesicle and postsynaptic protein handling before overt neuronal loss becomes dominant.
neuron link
chemical synaptic transmission link ↓ DECREASED
brain link
Downstream
Hyperactivity Early synaptic dysfunction is a plausible mediator of the prominent early behavioral phenotype.
Show evidence (1 reference)
PMID:22558223 SUPPORT Model Organism
"Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary..."
IIIA and IIIB mouse models both show cortical synaptic protein abnormalities consistent with neuronal dysfunction.
Progressive central neurodegeneration
The shared clinical trajectory across Sanfilippo syndrome is progressive central nervous system degeneration with worsening cognition, regression, and later premature death.
neuron link
brain link
Downstream
Intellectual disability Progressive CNS degeneration produces severe intellectual disability.
Developmental regression Progressive CNS degeneration leads to loss of previously acquired developmental skills.
Sleep disturbance Sleep disturbance is a common neurologic-behavioral consequence of the progressive CNS disease process.
Autism Autism-spectrum manifestations are part of the neurologic and behavioral output of progressive Sanfilippo CNS disease.
Atypical behavior Behavioral problems are part of the neurobehavioral expression of the progressive CNS disease process.
Seizure Seizures are neurologic complications managed as part of the Sanfilippo clinical spectrum.
Feeding difficulties Feeding difficulties are managed among the later neurologic and systemic complications of Sanfilippo syndrome.
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder..."
GeneReviews directly supports progressive CNS degeneration as the dominant disease-level consequence of Sanfilippo syndrome.
Systemic manifestations of glycosaminoglycan storage
Although neurologic decline dominates Sanfilippo syndrome, extraneural glycosaminoglycan storage produces a milder systemic branch involving musculoskeletal, auditory, respiratory, and cardiac manifestations.
lysosome link
Downstream
Joint stiffness Joint stiffness is one of the musculoskeletal manifestations in the systemic branch.
Joint contracture Contractures are part of the milder musculoskeletal involvement in MPS III.
Scoliosis Scoliosis is part of the musculoskeletal systemic branch.
Hip dysplasia Hip dysplasia is one of the musculoskeletal manifestations in the systemic branch.
Hearing impairment Hearing loss is part of the systemic Sanfilippo syndrome spectrum.
Respiratory tract infection Respiratory tract and sinopulmonary infections are part of systemic MPS III involvement and contribute to mortality.
Abnormal heart valve morphology Valvular thickening is a cardiac manifestation in the systemic branch.
Cardiac conduction abnormality Cardiac conduction defects are part of the systemic branch.
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system)."
GeneReviews supports this as the systemic clinical branch of MPS III.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Sanfilippo syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

16
Cardiovascular 2
Abnormal heart valve morphology Abnormal heart valve morphology (HP:0001654)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system)."
GeneReviews supports valve involvement by specifying cardiac valvular thickening.
Cardiac conduction abnormality Cardiac conduction abnormality (HP:0031546)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system)."
GeneReviews explicitly lists defects in the cardiac conduction system.
Digestive 1
Feeding difficulties Feeding difficulties (HP:0011968)
Show evidence (1 reference)
PMID:31536183 PARTIAL Other
"Treatment of manifestations: Supportive therapies for neurodevelopmental delays, hearing loss, and visual impairment; medications (rather than behavioral therapy) for psychiatric/behavioral issues; physical therapy and/or orthopedic management of musculoskeletal manifestations; and management as..."
GeneReviews includes feeding difficulties among MPS III manifestations requiring specialist management.
Ear 1
Hearing impairment Hearing impairment (HP:0000365)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system)."
GeneReviews explicitly lists hearing loss among systemic manifestations.
Musculoskeletal 4
Joint stiffness Joint stiffness (HP:0001387)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system)."
GeneReviews explicitly lists joint stiffness as a systemic manifestation.
Joint contracture Joint contracture (HP:0034392)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system)."
GeneReviews explicitly lists contractures as a systemic musculoskeletal manifestation.
Scoliosis Scoliosis (HP:0002650)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system)."
GeneReviews explicitly lists scoliosis as a systemic musculoskeletal manifestation.
Hip dysplasia Hip dysplasia (HP:0001385)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system)."
GeneReviews explicitly lists hip dysplasia as a systemic manifestation.
Nervous System 7
Intellectual disability Intellectual disability (HP:0001249)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder..."
GeneReviews explicitly identifies severe intellectual disability as a core clinical feature of Sanfilippo syndrome.
Developmental regression Developmental regression (HP:0002376)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder..."
GeneReviews directly supports developmental regression as a hallmark phenotype across the syndrome.
Hyperactivity Hyperactivity (HP:0000752)
Show evidence (1 reference)
PMID:25851924 SUPPORT Other
"It is characterized by progressive cognitive decline and severe hyperactivity, with relatively mild somatic features."
This review directly supports severe hyperactivity as a defining behavioral manifestation of Sanfilippo syndrome.
Sleep disturbance Sleep disturbance (HP:0002360)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder..."
GeneReviews directly supports sleep disturbance as a core neurologic- behavioral manifestation of the syndrome.
Autism Autism (HP:0000717)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder..."
GeneReviews explicitly identifies autism spectrum disorder among the neurologic manifestations of MPS III.
Atypical behavior Atypical behavior (HP:0000708)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder..."
GeneReviews explicitly includes behavioral problems among neurologic manifestations of progressive MPS III.
Seizure Seizure (HP:0001250)
Show evidence (1 reference)
PMID:31536183 PARTIAL Other
"Treatment of manifestations: Supportive therapies for neurodevelopmental delays, hearing loss, and visual impairment; medications (rather than behavioral therapy) for psychiatric/behavioral issues; physical therapy and/or orthopedic management of musculoskeletal manifestations; and management as..."
GeneReviews includes seizures among manifestations requiring specialist management in MPS III.
Other 1
Respiratory tract infection Respiratory tract infection (HP:0011947)
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system)."
GeneReviews explicitly lists respiratory tract and sinopulmonary infections among systemic manifestations.
💊

Treatments

3
Investigational gene therapy
Action: gene therapy MAXO:0001001
Subtype-specific gene restoration strategies are in development to restore the missing lysosomal enzyme step and lower heparan sulfate storage. The strongest abstract-level mechanistic support in this curation comes from SGSH-directed type A models.
Mechanism Target:
INHIBITS Lysosomal heparan sulfate accumulation — Liver-directed AAV-mediated sulfamidase expression reduced systemic and brain glycosaminoglycan storage in a subtype-A model.
Show evidence (1 reference)
PMID:22008915 SUPPORT Model Organism
"In contrast, AAV8-mediated liver-directed gene transfer achieved high and sustained levels of circulating active sulfamidase, which reached normal levels in females and was fourfold higher in males, and completely corrected lysosomal GAG accumulation in most somatic tissues. Remarkably, a 50%..."
This subtype-A gene therapy model shows direct inhibition of the core storage lesion in both peripheral tissues and brain.
Show evidence (1 reference)
PMID:25851924 SUPPORT Other
"Although there is no global consensus for treatment, enzyme replacement therapy and gene therapy can provide appropriate results."
This review supports inclusion of gene therapy as a leading investigational disease-modifying strategy across the Sanfilippo spectrum.
Substrate reduction therapy (genistein)
Action: substrate reduction therapy MAXO:0020025
Genistein has preclinical activity as a substrate reduction strategy in MPS IIIB, lowering storage burden, neuroinflammation, and behavioral abnormalities.
Mechanism Target:
INHIBITS Lysosomal heparan sulfate accumulation — Long-term genistein treatment reduced lysosomal storage and heparan sulfate substrate burden in the brain.
Show evidence (1 reference)
PMID:21152017 SUPPORT Model Organism
"We report here that high doses of genistein aglycone, given continuously over a 9 month period to MPSIIIB mice, significantly reduce lysosomal storage, heparan sulphate substrate and neuroinflammation in the cerebral cortex and hippocampus, resulting in correction of the behavioural defects observed."
This subtype-B preclinical study shows direct reduction of the core HS storage lesion by substrate reduction therapy.
INHIBITS Neuroinflammatory cascade — The same genistein regimen also reduced brain neuroinflammation.
Show evidence (1 reference)
PMID:21152017 SUPPORT Model Organism
"We report here that high doses of genistein aglycone, given continuously over a 9 month period to MPSIIIB mice, significantly reduce lysosomal storage, heparan sulphate substrate and neuroinflammation in the cerebral cortex and hippocampus, resulting in correction of the behavioural defects observed."
This study directly links genistein treatment to reduced neuroinflammatory brain pathology.
Show evidence (1 reference)
PMID:21152017 SUPPORT Model Organism
"Genistein may prove useful as a substrate reduction agent to delay clinical onset of MPSIIIB and, due to its multimodal action, may provide a treatment adjunct for several other neurodegenerative metabolic diseases."
This preclinical abstract supports genistein as an investigational substrate reduction approach relevant to the Sanfilippo spectrum.
Supportive symptomatic care
Action: supportive care MAXO:0000950
Management remains largely supportive, with medications and specialist care directed toward behavioral symptoms, sleep disturbance, seizures, and other complications.
Target Phenotypes: Hyperactivity ↗ Sleep disturbance ↗ Behavioral problems ↗ Seizure ↗ Feeding difficulties ↗ Hearing loss ↗ Joint stiffness ↗ Cardiac conduction abnormality ↗
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"Treatment of manifestations: Supportive therapies for neurodevelopmental delays, hearing loss, and visual impairment; medications (rather than behavioral therapy) for psychiatric/behavioral issues; physical therapy and/or orthopedic management of musculoskeletal manifestations; and management as..."
GeneReviews supports symptom-directed supportive management as the current standard-of-care framework for behavioral and sleep manifestations.
🔬

Biochemical Markers

4
Subtype-specific lysosomal enzyme activity (DECREASED)
Context: Low activity of the subtype-specific lysosomal enzyme confirms the Sanfilippo subtype together with molecular testing.
Pathograph Readouts
Readout Of Lysosomal heparan sulfate catabolism defect Negative Diagnostic
Decreased SGSH, NAGLU, HGSNAT, or GNS enzyme activity reports the root heparan-sulfate catabolic defect.
Show evidence (1 reference)
PMID:25851924 SUPPORT Other
"Enzyme activity of the different enzymes in blood serum, leukocytes or fibroblasts, and mutational analysis for SGSH, NAGLU, HGSNAT or GNS genes are required to confirm diagnosis and differentiate four subtypes of MPS III."
The review supports subtype-specific enzyme activity as a diagnostic readout of the causal enzymatic block.
Show evidence (1 reference)
PMID:31536183 SUPPORT Other
"The diagnosis of MPS III is established in a proband with suggestive clinical and laboratory findings in whom either biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified."
GeneReviews identifies deficiency of the respective lysosomal enzyme as a diagnostic route for MPS III.
Heparan sulfate (INCREASED)
Context: Heparan sulfate is the primary stored substrate in Sanfilippo syndrome and is elevated and abnormally sulfated in MPS III brain models.
Pathograph Readouts
Readout Of Lysosomal heparan sulfate accumulation Positive Diagnostic
Elevated heparan sulfate reports the proximal lysosomal storage lesion.
Show evidence (1 reference)
PMID:22558223 SUPPORT Model Organism
"Total heparan sulphate (HS), was significantly elevated, and abnormally N-, 6-O and 2-O sulphated compared to WT, potentially altering HS-dependent cellular functions."
MPS IIIA/IIIB mouse brain evidence directly supports increased total heparan sulfate as a readout of storage pathology.
Show evidence (1 reference)
PMID:22558223 SUPPORT Model Organism
"Total heparan sulphate (HS), was significantly elevated, and abnormally N-, 6-O and 2-O sulphated compared to WT, potentially altering HS-dependent cellular functions."
This supports heparan sulfate elevation as a measurable biochemical abnormality in MPS III models.
Urinary glycosaminoglycans (ABNORMAL)
Context: Urinary glycosaminoglycan quantification is a recommended diagnostic screen for Sanfilippo syndrome and reflects the broader stored GAG burden.
Pathograph Readouts
Readout Of Lysosomal heparan sulfate accumulation Positive Diagnostic
Abnormal urinary glycosaminoglycan analysis reports the lysosomal glycosaminoglycan storage axis.
Show evidence (1 reference)
PMID:25851924 SUPPORT Other
"Quantitative urinary glycosaminoglycan analysis is strongly recommended, and measurement of disaccharides, heparin cofactor II-thrombin complex and gangliosides is also used."
The review supports urinary glycosaminoglycan analysis as a diagnostic readout in MPS III.
Show evidence (1 reference)
PMID:25851924 SUPPORT Other
"Quantitative urinary glycosaminoglycan analysis is strongly recommended, and measurement of disaccharides, heparin cofactor II-thrombin complex and gangliosides is also used."
This diagnostic review supports urinary GAG analysis as a Sanfilippo biochemical readout.
GM2 ganglioside storage (INCREASED)
Context: Secondary GM2 ganglioside storage accompanies the lysosomal and neuroinflammatory abnormalities in MPS III brain pathology.
Pathograph Readouts
Readout Of Lysosomal heparan sulfate accumulation Positive Diagnostic
GM2 ganglioside storage reports secondary lysosomal storage in the MPS III CNS disease branch.
Show evidence (1 reference)
PMID:22558223 SUPPORT Model Organism
"Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary..."
The MPS IIIA/IIIB brain model documents GM2 ganglioside storage in the same cortical disease branch.
Show evidence (1 reference)
PMID:22558223 SUPPORT Model Organism
"Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary..."
This MPS IIIA/IIIB model supports GM2 ganglioside storage as a secondary biochemical abnormality.
{ }

Source YAML

click to show 
name: Sanfilippo syndrome
creation_date: '2026-04-14T19:55:38Z'
updated_date: '2026-05-20T13:53:50Z'
category: Mendelian
description: >-
  Sanfilippo syndrome, also called mucopolysaccharidosis type III (MPS III), is
  an autosomal recessive lysosomal storage disorder caused by deficiency of one
  of four enzymes required for heparan sulfate catabolism. The shared disease
  mechanism is failed lysosomal degradation of heparan sulfate, followed by
  heparan sulfate storage, neuroinflammation, cortical synaptic dysfunction, and
  progressive central nervous system degeneration. Clinically, the syndrome is
  dominated by progressive intellectual disability, developmental regression,
  autism-spectrum and other behavioral manifestations, hyperactivity, and sleep
  disturbance. Systemic involvement is comparatively mild relative to other
  mucopolysaccharidoses but can include musculoskeletal, hearing, respiratory,
  and cardiac manifestations.
disease_term:
  preferred_term: Sanfilippo syndrome
  term:
    id: MONDO:0018937
    label: mucopolysaccharidosis type 3
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0018937
      label: mucopolysaccharidosis type 3
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
parents:
- Mucopolysaccharidosis
- Lysosomal Storage Disorders
- Neurodegeneration
synonyms:
- mucopolysaccharidosis type III
- MPS III
- Sanfilippo disease
has_subtypes:
- name: MPS IIIA
  display_name: Sanfilippo syndrome type A (MPS IIIA)
  description: >-
    SGSH-related Sanfilippo syndrome caused by sulfamidase deficiency.
  subtype_term:
    preferred_term: Sanfilippo syndrome type A
    term:
      id: MONDO:0009655
      label: mucopolysaccharidosis type 3A
  genes:
  - preferred_term: SGSH
    term:
      id: hgnc:10818
      label: SGSH
  evidence:
  - reference: PMID:31536183
    reference_title: "Mucopolysaccharidosis Type III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU,
      and SGSH) or deficiency of the respective lysosomal enzyme has been
      identified
    explanation: >-
      The GeneReviews reference for MPS III identifies SGSH as one of the four
      causative genes for MPS III, with the MPS IIIA subtype specifically
      caused by biallelic pathogenic variants in SGSH (sulfamidase deficiency).
  - reference: CGGV:assertion_438dab6d-abf4-44e8-a176-bb39ae128052-2022-06-15T160000.000Z
    reference_title: "SGSH / mucopolysaccharidosis type 3A (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SGSH | HGNC:10818 | mucopolysaccharidosis type 3A | MONDO:0009655 | AR | Definitive"
    explanation: >-
      ClinGen's Lysosomal Diseases GCEP classifies the SGSH-MPS IIIA
      gene-disease relationship as Definitive with autosomal recessive
      inheritance.
- name: MPS IIIB
  display_name: Sanfilippo syndrome type B (MPS IIIB)
  description: >-
    NAGLU-related Sanfilippo syndrome caused by alpha-N-acetylglucosaminidase
    deficiency.
  subtype_term:
    preferred_term: Sanfilippo syndrome type B
    term:
      id: MONDO:0009656
      label: mucopolysaccharidosis type 3B
  genes:
  - preferred_term: NAGLU
    term:
      id: hgnc:7632
      label: NAGLU
  evidence:
  - reference: PMID:31536183
    reference_title: "Mucopolysaccharidosis Type III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU,
      and SGSH) or deficiency of the respective lysosomal enzyme has been
      identified
    explanation: >-
      The GeneReviews reference for MPS III identifies NAGLU as one of the four
      causative genes for MPS III, with the MPS IIIB subtype specifically
      caused by biallelic pathogenic variants in NAGLU (alpha-N-acetylglucosaminidase
      deficiency).
  - reference: CGGV:assertion_7ee5629a-f6c2-4187-a802-d570f7180478-2022-08-22T160000.000Z
    reference_title: "NAGLU / mucopolysaccharidosis type 3B (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NAGLU | HGNC:7632 | mucopolysaccharidosis type 3B | MONDO:0009656 | AR | Definitive"
    explanation: >-
      ClinGen's Lysosomal Diseases GCEP classifies the NAGLU-MPS IIIB
      gene-disease relationship as Definitive with autosomal recessive
      inheritance.
- name: MPS IIIC
  display_name: Sanfilippo syndrome type C (MPS IIIC)
  description: >-
    HGSNAT-related Sanfilippo syndrome caused by heparan-alpha-glucosaminide
    N-acetyltransferase deficiency.
  subtype_term:
    preferred_term: Sanfilippo syndrome type C
    term:
      id: MONDO:0009657
      label: mucopolysaccharidosis type 3C
  genes:
  - preferred_term: HGSNAT
    term:
      id: hgnc:26527
      label: HGSNAT
  evidence:
  - reference: PMID:31536183
    reference_title: "Mucopolysaccharidosis Type III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU,
      and SGSH) or deficiency of the respective lysosomal enzyme has been
      identified
    explanation: >-
      The GeneReviews reference for MPS III identifies HGSNAT as one of the four
      causative genes for MPS III, with the MPS IIIC subtype specifically
      caused by biallelic pathogenic variants in HGSNAT (heparan-alpha-glucosaminide
      N-acetyltransferase deficiency).
  - reference: CGGV:assertion_943b7a75-eb7f-415b-ba80-de6b09cc5a43-2023-12-04T170000.000Z
    reference_title: "HGSNAT / mucopolysaccharidosis type 3C (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HGSNAT | HGNC:26527 | mucopolysaccharidosis type 3C | MONDO:0009657 | AR | Definitive"
    explanation: >-
      ClinGen's Lysosomal Diseases GCEP classifies the HGSNAT-MPS IIIC
      gene-disease relationship as Definitive with autosomal recessive
      inheritance.
- name: MPS IIID
  display_name: Sanfilippo syndrome type D (MPS IIID)
  description: >-
    GNS-related Sanfilippo syndrome caused by N-acetylglucosamine-6-sulfatase
    deficiency.
  subtype_term:
    preferred_term: Sanfilippo syndrome type D
    term:
      id: MONDO:0009658
      label: mucopolysaccharidosis type 3D
  genes:
  - preferred_term: GNS
    term:
      id: hgnc:4422
      label: GNS
  evidence:
  - reference: PMID:31536183
    reference_title: "Mucopolysaccharidosis Type III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU,
      and SGSH) or deficiency of the respective lysosomal enzyme has been
      identified
    explanation: >-
      The GeneReviews reference for MPS III identifies GNS as one of the four
      causative genes for MPS III, with the MPS IIID subtype specifically
      caused by biallelic pathogenic variants in GNS (N-acetylglucosamine-6-sulfatase
      deficiency).
  - reference: CGGV:assertion_63312833-baef-4b11-9769-c93957decef6-2022-09-02T160000.000Z
    reference_title: "GNS / mucopolysaccharidosis type 3D (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GNS | HGNC:4422 | mucopolysaccharidosis type 3D | MONDO:0009658 | AR | Definitive"
    explanation: >-
      ClinGen's Lysosomal Diseases GCEP classifies the GNS-MPS IIID
      gene-disease relationship as Definitive with autosomal recessive
      inheritance.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    All four Sanfilippo subtypes are inherited as autosomal recessive disorders.
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: MPS III is inherited in an autosomal recessive manner.
    explanation: >-
      GeneReviews explicitly states that the Sanfilippo syndrome spectrum is
      inherited in an autosomal recessive manner.
progression:
- phase: Childhood neurobehavioral onset
  age_range: typically before age 10 years
  notes: >-
    Sanfilippo syndrome usually begins in childhood with a neurobehavioral
    presentation and may follow either a rapidly progressive or a more slowly
    progressive course.
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Disease onset is typically before age ten years.
    explanation: >-
      GeneReviews supports childhood onset as the usual entry point into the
      disease course.
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Disease course may be rapidly or slowly progressive; some individuals with an extremely attenuated disease course present in mid-to-late adulthood with early-onset dementia with or without a history of ID.
    explanation: >-
      This review supports modeling Sanfilippo syndrome as a shared spectrum
      with variable tempo, including attenuated forms.
- phase: Progressive neurologic decline and shortened survival
  notes: >-
    Neurologic decline is universal across the syndrome, although severity
    varies within and among subtypes.
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Neurologic decline is seen in all affected individuals; however, clinical severity varies within and among the four MPS III subtypes (defined by the enzyme involved) and even among members of the same family.
    explanation: >-
      GeneReviews supports universal neurologic decline across the syndrome
      while preserving subtype- and family-level variability.
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Death usually occurs in the second or third decade of life secondary to neurologic regression or respiratory tract infections.
    explanation: >-
      This review supports shortened survival from progressive neurologic and
      systemic complications.
pathophysiology:
- name: Lysosomal heparan sulfate catabolism defect
  description: >-
    The root disease mechanism is deficiency of one of four lysosomal enzymes
    required for the stepwise degradation of heparan sulfate.
  genes:
  - preferred_term: SGSH
    term:
      id: hgnc:10818
      label: SGSH
  - preferred_term: NAGLU
    term:
      id: hgnc:7632
      label: NAGLU
  - preferred_term: HGSNAT
    term:
      id: hgnc:26527
      label: HGSNAT
  - preferred_term: GNS
    term:
      id: hgnc:4422
      label: GNS
  molecular_functions:
  - preferred_term: N-sulfoglucosamine sulfohydrolase activity
    modifier: DECREASED
    term:
      id: GO:0016250
      label: N-sulfoglucosamine sulfohydrolase activity
  - preferred_term: alpha-N-acetylglucosaminidase activity
    modifier: DECREASED
    term:
      id: GO:0004561
      label: alpha-N-acetylglucosaminidase activity
  - preferred_term: heparan-alpha-glucosaminide N-acetyltransferase activity
    modifier: DECREASED
    term:
      id: GO:0015019
      label: heparan-alpha-glucosaminide N-acetyltransferase activity
  - preferred_term: N-acetylglucosamine-6-sulfatase activity
    modifier: DECREASED
    term:
      id: GO:0008449
      label: N-acetylglucosamine-6-sulfatase activity
  biological_processes:
  - preferred_term: heparan sulfate catabolism
    modifier: DECREASED
    term:
      id: GO:0006027
      label: glycosaminoglycan catabolic process
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:25851924
    reference_title: 'Sanfilippo syndrome: Overall review.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) is a lysosomal storage disorder, caused by a deficiency in one of the four enzymes involved in the catabolism of glycosaminoglycan heparan sulfate.
    explanation: >-
      This review supports a shared root mechanism upstream of the four
      Sanfilippo subtypes: failure of lysosomal heparan sulfate catabolism.
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of MPS III is established in a proband with suggestive clinical and laboratory findings in whom either biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified.
    explanation: >-
      GeneReviews confirms that the shared root disorder is genetically split
      across four subtype-defining lysosomal enzyme genes.
  downstream:
  - target: Lysosomal heparan sulfate accumulation
    description: >-
      Failed lysosomal catabolism leads to storage of partially degraded heparan
      sulfate.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36306823
      reference_title: Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Enzyme deficiency results in accumulation of partially degraded HS within lysosomes throughout the body, leading to a progressive severe neurological disease.
      explanation: >-
        A subtype-A model directly supports the shared proximal biochemical
        consequence of failed heparan sulfate catabolism: lysosomal HS storage.
  - target: Subtype-specific lysosomal enzyme activity
    description: >-
      The same upstream enzymatic lesion is detected diagnostically as decreased
      activity of the subtype-specific lysosomal enzyme.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The diagnosis of MPS III is established in a proband with suggestive clinical and laboratory findings in whom either biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified.
      explanation: >-
        GeneReviews supports deficient subtype-specific enzyme activity as a
        direct diagnostic readout of the root catabolic defect.
- name: Lysosomal heparan sulfate accumulation
  description: >-
    Partially degraded heparan sulfate accumulates within lysosomes and becomes
    the biochemical lesion that drives downstream brain pathology.
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  chemical_entities:
  - preferred_term: heparan sulfate
    term:
      id: CHEBI:28815
      label: heparan sulfate
    modifier: INCREASED
  - preferred_term: glycosaminoglycan
    term:
      id: CHEBI:18085
      label: glycosaminoglycan
    modifier: INCREASED
  evidence:
  - reference: PMID:36306823
    reference_title: Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Enzyme deficiency results in accumulation of partially degraded HS within lysosomes throughout the body, leading to a progressive severe neurological disease.
    explanation: >-
      This preclinical abstract directly supports lysosomal heparan sulfate
      storage as the immediate consequence of enzyme deficiency.
  downstream:
  - target: Neuroinflammatory cascade
    description: >-
      Heparan sulfate storage triggers a neuroinflammatory response in the
      brain.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37794029
      reference_title: Disease pathology signatures in a mouse model of Mucopolysaccharidosis type IIIB.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: The lack of functional enzyme in MPS IIIB patients leads to the progressive accumulation of heparan sulfate throughout the body and triggers a cascade of neuroinflammatory and other biochemical processes ultimately resulting in severe mental impairment and early death in adolescence or young adulthood.
      explanation: >-
        A subtype-B model directly links heparan sulfate accumulation to a
        downstream neuroinflammatory cascade.
  - target: Cortical synaptic dysfunction
    description: >-
      Heparan sulfate oligosaccharides perturb synaptic vesicle protein
      homeostasis in cortical neurons.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19386237
      reference_title: Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Clearance of heparan sulfate oligosaccharides in cultured embryonic MPSIIIB cortical neurons or treatment with proteasome inhibitors restored normal synaptophysin levels indicating that heparan sulfate oligosaccharides activate the degradation of synaptophysin by the proteasome with consequences on synaptic vesicle components that are relevant to clinical manifestations.
      explanation: >-
        This mechanistic subtype-B study directly connects heparan sulfate
        oligosaccharide storage to synaptic vesicle dysfunction in cortical
        neurons.
  - target: Systemic manifestations of glycosaminoglycan storage
    description: >-
      Lysosomal heparan sulfate storage also has extraneural systemic effects,
      including musculoskeletal, hearing, respiratory, and cardiac involvement.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - extraneural glycosaminoglycan storage in somatic tissues
    evidence:
    - reference: PMID:22008915
      reference_title: Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice.
      supports: PARTIAL
      evidence_source: MODEL_ORGANISM
      snippet: Mucopolysaccharidosis type IIIA (MPSIIIA) is an inherited lysosomal storage disease caused by deficiency of sulfamidase, resulting in accumulation of the glycosaminoglycan (GAG) heparan sulfate. It is characterized by severe progressive neurodegeneration, together with somatic alterations, which lead to death during adolescence.
      explanation: >-
        This subtype-A model abstract supports somatic alterations downstream of
        the same heparan-sulfate storage axis.
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
      explanation: >-
        GeneReviews summarizes the systemic clinical branch that accompanies the
        Sanfilippo syndrome spectrum.
  - target: Heparan sulfate
    description: >-
      Increased heparan sulfate reports the stored substrate in Sanfilippo
      syndrome.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22558223
      reference_title: Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Total heparan sulphate (HS), was significantly elevated, and abnormally N-, 6-O and 2-O sulphated compared to WT, potentially altering HS-dependent cellular functions.
      explanation: >-
        Mouse MPS IIIA/IIIB evidence directly supports elevated total heparan
        sulfate as a storage readout.
  - target: Urinary glycosaminoglycans
    description: >-
      Quantitative urinary glycosaminoglycan analysis is used as a diagnostic
      readout of Sanfilippo glycosaminoglycan storage.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - accumulated glycosaminoglycans measured in urine
    evidence:
    - reference: PMID:25851924
      reference_title: 'Sanfilippo syndrome: Overall review.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Quantitative urinary glycosaminoglycan analysis is strongly recommended, and measurement of disaccharides, heparin cofactor II-thrombin complex and gangliosides is also used.
      explanation: >-
        This review supports urinary glycosaminoglycans as a diagnostic readout
        of the storage disorder.
  - target: GM2 ganglioside storage
    description: >-
      GM2 ganglioside storage is a secondary biochemical abnormality in
      neurodegenerative MPS III brain pathology.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - secondary lysosomal lipid storage in affected brain regions
    evidence:
    - reference: PMID:22558223
      reference_title: Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary motor, somatosensory and parietal cortex.
      explanation: >-
        MPS IIIA/IIIB mouse brain pathology directly documents GM2 ganglioside
        storage alongside lysosomal and inflammatory abnormalities.
- name: Neuroinflammatory cascade
  description: >-
    Brain heparan sulfate storage is accompanied by microglial, astrocytic, and
    cytokine evidence of neuroinflammation.
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:22558223
    reference_title: Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary motor, somatosensory and parietal cortex.
    explanation: >-
      IIIA and IIIB mouse models both show explicit neuroinflammatory brain
      pathology alongside lysosomal storage.
  downstream:
  - target: Progressive central neurodegeneration
    description: >-
      The inflammatory cascade is part of the progressive brain pathology that
      culminates in severe neurologic decline.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37794029
      reference_title: Disease pathology signatures in a mouse model of Mucopolysaccharidosis type IIIB.
      supports: PARTIAL
      evidence_source: MODEL_ORGANISM
      snippet: The lack of functional enzyme in MPS IIIB patients leads to the progressive accumulation of heparan sulfate throughout the body and triggers a cascade of neuroinflammatory and other biochemical processes ultimately resulting in severe mental impairment and early death in adolescence or young adulthood.
      explanation: >-
        This subtype-B abstract supports neuroinflammation as one of the key
        intermediary processes leading to severe neurologic decline and early
        death.
- name: Cortical synaptic dysfunction
  description: >-
    Sanfilippo syndrome includes early cortical synaptic dysfunction with
    abnormal synaptic vesicle and postsynaptic protein handling before overt
    neuronal loss becomes dominant.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: chemical synaptic transmission
    modifier: DECREASED
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:22558223
    reference_title: Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary motor, somatosensory and parietal cortex.
    explanation: >-
      IIIA and IIIB mouse models both show cortical synaptic protein
      abnormalities consistent with neuronal dysfunction.
  downstream:
  - target: Hyperactivity
    description: >-
      Early synaptic dysfunction is a plausible mediator of the prominent early
      behavioral phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19386237
      reference_title: Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB.
      supports: PARTIAL
      evidence_source: MODEL_ORGANISM
      snippet: Behavioural manifestations are prominent at disease onset, suggesting possible early synaptic defects in cortical neurons.
      explanation: >-
        This study explicitly links prominent early behavioral manifestations to
        early cortical synaptic defects.
- name: Progressive central neurodegeneration
  description: >-
    The shared clinical trajectory across Sanfilippo syndrome is progressive
    central nervous system degeneration with worsening cognition, regression, and
    later premature death.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
    explanation: >-
      GeneReviews directly supports progressive CNS degeneration as the dominant
      disease-level consequence of Sanfilippo syndrome.
  downstream:
  - target: Intellectual disability
    description: >-
      Progressive CNS degeneration produces severe intellectual disability.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
      explanation: >-
        GeneReviews explicitly places severe intellectual disability within the
        clinical expression of progressive CNS degeneration.
  - target: Developmental regression
    description: >-
      Progressive CNS degeneration leads to loss of previously acquired
      developmental skills.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
      explanation: >-
        GeneReviews directly supports developmental regression as a consequence
        of the progressive CNS disease process.
  - target: Sleep disturbance
    description: >-
      Sleep disturbance is a common neurologic-behavioral consequence of the
      progressive CNS disease process.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
      explanation: >-
        This review places sleep disturbance within the clinical output of the
        progressive CNS disease process.
  - target: Autism
    description: >-
      Autism-spectrum manifestations are part of the neurologic and behavioral
      output of progressive Sanfilippo CNS disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
      explanation: >-
        GeneReviews explicitly includes autism spectrum disorder among the
        manifestations of progressive CNS degeneration.
  - target: Atypical behavior
    description: >-
      Behavioral problems are part of the neurobehavioral expression of the
      progressive CNS disease process.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
      explanation: >-
        GeneReviews places behavioral problems downstream of progressive CNS
        degeneration in Sanfilippo syndrome.
  - target: Seizure
    description: >-
      Seizures are neurologic complications managed as part of the Sanfilippo
      clinical spectrum.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive neurologic decline
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: PARTIAL
      evidence_source: OTHER
      snippet: >-
        Treatment of manifestations: Supportive therapies for neurodevelopmental
        delays, hearing loss, and visual impairment; medications (rather than
        behavioral therapy) for psychiatric/behavioral issues; physical therapy
        and/or orthopedic management of musculoskeletal manifestations; and
        management as prescribed by consulting specialists for seizures, cardiac
        involvement, sleep disorders, feeding difficulties.
      explanation: >-
        GeneReviews management guidance names seizures among specialist-managed
        manifestations of MPS III.
  - target: Feeding difficulties
    description: >-
      Feeding difficulties are managed among the later neurologic and systemic
      complications of Sanfilippo syndrome.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive neurologic decline and multisystem involvement
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: PARTIAL
      evidence_source: OTHER
      snippet: >-
        Treatment of manifestations: Supportive therapies for neurodevelopmental
        delays, hearing loss, and visual impairment; medications (rather than
        behavioral therapy) for psychiatric/behavioral issues; physical therapy
        and/or orthopedic management of musculoskeletal manifestations; and
        management as prescribed by consulting specialists for seizures, cardiac
        involvement, sleep disorders, feeding difficulties.
      explanation: >-
        GeneReviews management guidance identifies feeding difficulties as an
        MPS III manifestation requiring specialist management.
- name: Systemic manifestations of glycosaminoglycan storage
  description: >-
    Although neurologic decline dominates Sanfilippo syndrome, extraneural
    glycosaminoglycan storage produces a milder systemic branch involving
    musculoskeletal, auditory, respiratory, and cardiac manifestations.
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  chemical_entities:
  - preferred_term: heparan sulfate
    term:
      id: CHEBI:28815
      label: heparan sulfate
    modifier: INCREASED
  - preferred_term: glycosaminoglycan
    term:
      id: CHEBI:18085
      label: glycosaminoglycan
    modifier: INCREASED
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
    explanation: >-
      GeneReviews supports this as the systemic clinical branch of MPS III.
  downstream:
  - target: Joint stiffness
    description: >-
      Joint stiffness is one of the musculoskeletal manifestations in the
      systemic branch.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
      explanation: >-
        GeneReviews explicitly lists joint stiffness among systemic
        manifestations.
  - target: Joint contracture
    description: >-
      Contractures are part of the milder musculoskeletal involvement in MPS III.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
      explanation: >-
        GeneReviews explicitly lists contractures among systemic manifestations.
  - target: Scoliosis
    description: >-
      Scoliosis is part of the musculoskeletal systemic branch.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
      explanation: >-
        GeneReviews explicitly lists scoliosis among systemic manifestations.
  - target: Hip dysplasia
    description: >-
      Hip dysplasia is one of the musculoskeletal manifestations in the systemic
      branch.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
      explanation: >-
        GeneReviews explicitly lists hip dysplasia among systemic
        manifestations.
  - target: Hearing impairment
    description: >-
      Hearing loss is part of the systemic Sanfilippo syndrome spectrum.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
      explanation: >-
        GeneReviews explicitly lists hearing loss among systemic manifestations.
  - target: Respiratory tract infection
    description: >-
      Respiratory tract and sinopulmonary infections are part of systemic MPS III
      involvement and contribute to mortality.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
      explanation: >-
        GeneReviews explicitly lists respiratory tract and sinopulmonary
        infections among systemic manifestations.
  - target: Abnormal heart valve morphology
    description: >-
      Valvular thickening is a cardiac manifestation in the systemic branch.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
      explanation: >-
        GeneReviews specifies valvular thickening as a cardiac manifestation.
  - target: Cardiac conduction abnormality
    description: >-
      Cardiac conduction defects are part of the systemic branch.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31536183
      reference_title: Mucopolysaccharidosis Type III.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
      explanation: >-
        GeneReviews explicitly lists defects in the cardiac conduction system.
phenotypes:
- name: Intellectual disability
  category: Neurologic
  description: >-
    Progressive intellectual disability is one of the dominant central nervous
    system manifestations across the Sanfilippo spectrum.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
    explanation: >-
      GeneReviews explicitly identifies severe intellectual disability as a core
      clinical feature of Sanfilippo syndrome.
- name: Developmental regression
  category: Neurologic
  description: >-
    Loss of previously acquired developmental skills is a hallmark of
    progressive Sanfilippo syndrome.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
    explanation: >-
      GeneReviews directly supports developmental regression as a hallmark
      phenotype across the syndrome.
- name: Hyperactivity
  category: Behavioral
  description: >-
    Severe hyperactivity is a prominent early behavioral manifestation of the
    syndrome.
  phenotype_term:
    preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  evidence:
  - reference: PMID:25851924
    reference_title: 'Sanfilippo syndrome: Overall review.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It is characterized by progressive cognitive decline and severe hyperactivity, with relatively mild somatic features.
    explanation: >-
      This review directly supports severe hyperactivity as a defining
      behavioral manifestation of Sanfilippo syndrome.
- name: Sleep disturbance
  category: Behavioral
  description: >-
    Sleep disturbance is a common neurobehavioral manifestation across the
    syndrome.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
    explanation: >-
      GeneReviews directly supports sleep disturbance as a core neurologic-
      behavioral manifestation of the syndrome.
- name: Autism
  category: Behavioral
  description: >-
    Autism-spectrum manifestations are included among the neurologic and
    behavioral features of Sanfilippo syndrome.
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
    explanation: >-
      GeneReviews explicitly identifies autism spectrum disorder among the
      neurologic manifestations of MPS III.
- name: Atypical behavior
  category: Behavioral
  description: >-
    Behavioral problems are a core part of the Sanfilippo neurobehavioral
    presentation.
  phenotype_term:
    preferred_term: Behavioral problems
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances.
    explanation: >-
      GeneReviews explicitly includes behavioral problems among neurologic
      manifestations of progressive MPS III.
- name: Seizure
  category: Neurologic
  description: >-
    Seizures are recognized neurologic complications requiring specialist
    management in MPS III.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      Treatment of manifestations: Supportive therapies for neurodevelopmental
      delays, hearing loss, and visual impairment; medications (rather than
      behavioral therapy) for psychiatric/behavioral issues; physical therapy
      and/or orthopedic management of musculoskeletal manifestations; and
      management as prescribed by consulting specialists for seizures, cardiac
      involvement, sleep disorders, feeding difficulties.
    explanation: >-
      GeneReviews includes seizures among manifestations requiring specialist
      management in MPS III.
- name: Feeding difficulties
  category: Gastrointestinal
  description: >-
    Feeding difficulties are part of the managed clinical complications in MPS
    III.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      Treatment of manifestations: Supportive therapies for neurodevelopmental
      delays, hearing loss, and visual impairment; medications (rather than
      behavioral therapy) for psychiatric/behavioral issues; physical therapy
      and/or orthopedic management of musculoskeletal manifestations; and
      management as prescribed by consulting specialists for seizures, cardiac
      involvement, sleep disorders, feeding difficulties.
    explanation: >-
      GeneReviews includes feeding difficulties among MPS III manifestations
      requiring specialist management.
- name: Joint stiffness
  category: Musculoskeletal
  description: >-
    Joint stiffness is a systemic musculoskeletal manifestation in the Sanfilippo
    syndrome spectrum.
  phenotype_term:
    preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
    explanation: >-
      GeneReviews explicitly lists joint stiffness as a systemic manifestation.
- name: Joint contracture
  category: Musculoskeletal
  description: >-
    Contractures are part of the musculoskeletal branch of MPS III.
  phenotype_term:
    preferred_term: Joint contracture
    term:
      id: HP:0034392
      label: Joint contracture
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
    explanation: >-
      GeneReviews explicitly lists contractures as a systemic musculoskeletal
      manifestation.
- name: Scoliosis
  category: Musculoskeletal
  description: >-
    Scoliosis can occur as part of the systemic musculoskeletal involvement.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
    explanation: >-
      GeneReviews explicitly lists scoliosis as a systemic musculoskeletal
      manifestation.
- name: Hip dysplasia
  category: Musculoskeletal
  description: >-
    Hip dysplasia is part of the milder systemic musculoskeletal involvement in
    MPS III.
  phenotype_term:
    preferred_term: Hip dysplasia
    term:
      id: HP:0001385
      label: Hip dysplasia
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
    explanation: >-
      GeneReviews explicitly lists hip dysplasia as a systemic manifestation.
- name: Hearing impairment
  category: Auditory
  description: >-
    Hearing loss is a systemic manifestation in the Sanfilippo syndrome
    spectrum.
  phenotype_term:
    preferred_term: Hearing loss
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
    explanation: >-
      GeneReviews explicitly lists hearing loss among systemic manifestations.
- name: Respiratory tract infection
  category: Respiratory
  description: >-
    Respiratory tract and sinopulmonary infections are part of the systemic MPS
    III spectrum and can contribute to shortened survival.
  phenotype_term:
    preferred_term: Respiratory tract infection
    term:
      id: HP:0011947
      label: Respiratory tract infection
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
    explanation: >-
      GeneReviews explicitly lists respiratory tract and sinopulmonary
      infections among systemic manifestations.
- name: Abnormal heart valve morphology
  category: Cardiovascular
  description: >-
    Cardiac valve thickening is part of Sanfilippo cardiac involvement.
  phenotype_term:
    preferred_term: Abnormal heart valve morphology
    term:
      id: HP:0001654
      label: Abnormal heart valve morphology
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
    explanation: >-
      GeneReviews supports valve involvement by specifying cardiac valvular
      thickening.
- name: Cardiac conduction abnormality
  category: Cardiovascular
  description: >-
    Defects in the cardiac conduction system are part of Sanfilippo cardiac
    involvement.
  phenotype_term:
    preferred_term: Cardiac conduction abnormality
    term:
      id: HP:0031546
      label: Cardiac conduction abnormality
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Systemic manifestations can include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system).
    explanation: >-
      GeneReviews explicitly lists defects in the cardiac conduction system.
biochemical:
- name: Subtype-specific lysosomal enzyme activity
  presence: DECREASED
  context: >-
    Low activity of the subtype-specific lysosomal enzyme confirms the
    Sanfilippo subtype together with molecular testing.
  readouts:
  - target: Lysosomal heparan sulfate catabolism defect
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Decreased SGSH, NAGLU, HGSNAT, or GNS enzyme activity reports the root
      heparan-sulfate catabolic defect.
    evidence:
    - reference: PMID:25851924
      reference_title: 'Sanfilippo syndrome: Overall review.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Enzyme activity of the different enzymes in blood serum, leukocytes or fibroblasts, and mutational analysis for SGSH, NAGLU, HGSNAT or GNS genes are required to confirm diagnosis and differentiate four subtypes of MPS III.
      explanation: >-
        The review supports subtype-specific enzyme activity as a diagnostic
        readout of the causal enzymatic block.
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of MPS III is established in a proband with suggestive clinical and laboratory findings in whom either biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified.
    explanation: >-
      GeneReviews identifies deficiency of the respective lysosomal enzyme as a
      diagnostic route for MPS III.
- name: Heparan sulfate
  biomarker_term:
    preferred_term: heparan sulfate
    term:
      id: CHEBI:28815
      label: heparan sulfate
  presence: INCREASED
  context: >-
    Heparan sulfate is the primary stored substrate in Sanfilippo syndrome and
    is elevated and abnormally sulfated in MPS III brain models.
  readouts:
  - target: Lysosomal heparan sulfate accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Elevated heparan sulfate reports the proximal lysosomal storage lesion.
    evidence:
    - reference: PMID:22558223
      reference_title: Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Total heparan sulphate (HS), was significantly elevated, and abnormally N-, 6-O and 2-O sulphated compared to WT, potentially altering HS-dependent cellular functions.
      explanation: >-
        MPS IIIA/IIIB mouse brain evidence directly supports increased total
        heparan sulfate as a readout of storage pathology.
  evidence:
  - reference: PMID:22558223
    reference_title: Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Total heparan sulphate (HS), was significantly elevated, and abnormally N-, 6-O and 2-O sulphated compared to WT, potentially altering HS-dependent cellular functions.
    explanation: >-
      This supports heparan sulfate elevation as a measurable biochemical
      abnormality in MPS III models.
- name: Urinary glycosaminoglycans
  biomarker_term:
    preferred_term: glycosaminoglycan
    term:
      id: CHEBI:18085
      label: glycosaminoglycan
  presence: ABNORMAL
  context: >-
    Urinary glycosaminoglycan quantification is a recommended diagnostic screen
    for Sanfilippo syndrome and reflects the broader stored GAG burden.
  readouts:
  - target: Lysosomal heparan sulfate accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Abnormal urinary glycosaminoglycan analysis reports the lysosomal
      glycosaminoglycan storage axis.
    evidence:
    - reference: PMID:25851924
      reference_title: 'Sanfilippo syndrome: Overall review.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Quantitative urinary glycosaminoglycan analysis is strongly recommended, and measurement of disaccharides, heparin cofactor II-thrombin complex and gangliosides is also used.
      explanation: >-
        The review supports urinary glycosaminoglycan analysis as a diagnostic
        readout in MPS III.
  evidence:
  - reference: PMID:25851924
    reference_title: 'Sanfilippo syndrome: Overall review.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Quantitative urinary glycosaminoglycan analysis is strongly recommended, and measurement of disaccharides, heparin cofactor II-thrombin complex and gangliosides is also used.
    explanation: >-
      This diagnostic review supports urinary GAG analysis as a Sanfilippo
      biochemical readout.
- name: GM2 ganglioside storage
  biomarker_term:
    preferred_term: GM2 ganglioside
    term:
      id: CHEBI:141420
      label: ganglioside GM2 (natural compound)
  presence: INCREASED
  context: >-
    Secondary GM2 ganglioside storage accompanies the lysosomal and
    neuroinflammatory abnormalities in MPS III brain pathology.
  readouts:
  - target: Lysosomal heparan sulfate accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      GM2 ganglioside storage reports secondary lysosomal storage in the MPS III
      CNS disease branch.
    evidence:
    - reference: PMID:22558223
      reference_title: Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary motor, somatosensory and parietal cortex.
      explanation: >-
        The MPS IIIA/IIIB brain model documents GM2 ganglioside storage in the
        same cortical disease branch.
  evidence:
  - reference: PMID:22558223
    reference_title: Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary motor, somatosensory and parietal cortex.
    explanation: >-
      This MPS IIIA/IIIB model supports GM2 ganglioside storage as a secondary
      biochemical abnormality.
treatments:
- name: Investigational gene therapy
  description: >-
    Subtype-specific gene restoration strategies are in development to restore
    the missing lysosomal enzyme step and lower heparan sulfate storage. The
    strongest abstract-level mechanistic support in this curation comes from
    SGSH-directed type A models.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: Lysosomal heparan sulfate accumulation
    treatment_effect: INHIBITS
    description: >-
      Liver-directed AAV-mediated sulfamidase expression reduced systemic and
      brain glycosaminoglycan storage in a subtype-A model.
    evidence:
    - reference: PMID:22008915
      reference_title: Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In contrast, AAV8-mediated liver-directed gene transfer achieved high and sustained levels of circulating active sulfamidase, which reached normal levels in females and was fourfold higher in males, and completely corrected lysosomal GAG accumulation in most somatic tissues. Remarkably, a 50% reduction of GAG accumulation was achieved throughout the entire brain of males, which correlated with a partial improvement of the pathology of cerebellum and cortex.
      explanation: >-
        This subtype-A gene therapy model shows direct inhibition of the core
        storage lesion in both peripheral tissues and brain.
  evidence:
  - reference: PMID:25851924
    reference_title: 'Sanfilippo syndrome: Overall review.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Although there is no global consensus for treatment, enzyme replacement therapy and gene therapy can provide appropriate results.
    explanation: >-
      This review supports inclusion of gene therapy as a leading investigational
      disease-modifying strategy across the Sanfilippo spectrum.
- name: Substrate reduction therapy (genistein)
  description: >-
    Genistein has preclinical activity as a substrate reduction strategy in
    MPS IIIB, lowering storage burden, neuroinflammation, and behavioral
    abnormalities.
  treatment_term:
    preferred_term: substrate reduction therapy
    term:
      id: MAXO:0020025
      label: substrate reduction therapy
  target_mechanisms:
  - target: Lysosomal heparan sulfate accumulation
    treatment_effect: INHIBITS
    description: >-
      Long-term genistein treatment reduced lysosomal storage and heparan
      sulfate substrate burden in the brain.
    evidence:
    - reference: PMID:21152017
      reference_title: Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We report here that high doses of genistein aglycone, given continuously over a 9 month period to MPSIIIB mice, significantly reduce lysosomal storage, heparan sulphate substrate and neuroinflammation in the cerebral cortex and hippocampus, resulting in correction of the behavioural defects observed.
      explanation: >-
        This subtype-B preclinical study shows direct reduction of the core HS
        storage lesion by substrate reduction therapy.
  - target: Neuroinflammatory cascade
    treatment_effect: INHIBITS
    description: >-
      The same genistein regimen also reduced brain neuroinflammation.
    evidence:
    - reference: PMID:21152017
      reference_title: Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We report here that high doses of genistein aglycone, given continuously over a 9 month period to MPSIIIB mice, significantly reduce lysosomal storage, heparan sulphate substrate and neuroinflammation in the cerebral cortex and hippocampus, resulting in correction of the behavioural defects observed.
      explanation: >-
        This study directly links genistein treatment to reduced
        neuroinflammatory brain pathology.
  evidence:
  - reference: PMID:21152017
    reference_title: Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Genistein may prove useful as a substrate reduction agent to delay clinical onset of MPSIIIB and, due to its multimodal action, may provide a treatment adjunct for several other neurodegenerative metabolic diseases.
    explanation: >-
      This preclinical abstract supports genistein as an investigational
      substrate reduction approach relevant to the Sanfilippo spectrum.
- name: Supportive symptomatic care
  description: >-
    Management remains largely supportive, with medications and specialist care
    directed toward behavioral symptoms, sleep disturbance, seizures, and other
    complications.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  - preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  - preferred_term: Behavioral problems
    term:
      id: HP:0000708
      label: Atypical behavior
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  - preferred_term: Hearing loss
    term:
      id: HP:0000365
      label: Hearing impairment
  - preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
  - preferred_term: Cardiac conduction abnormality
    term:
      id: HP:0031546
      label: Cardiac conduction abnormality
  evidence:
  - reference: PMID:31536183
    reference_title: Mucopolysaccharidosis Type III.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Treatment of manifestations: Supportive therapies for neurodevelopmental
      delays, hearing loss, and visual impairment; medications (rather than
      behavioral therapy) for psychiatric/behavioral issues; physical therapy
      and/or orthopedic management of musculoskeletal manifestations; and
      management as prescribed by consulting specialists for seizures, cardiac
      involvement, sleep disorders, feeding difficulties.
    explanation: >-
      GeneReviews supports symptom-directed supportive management as the current
      standard-of-care framework for behavioral and sleep manifestations.
  notes: >-
    The same GeneReviews summary states that no treatments are currently
    clinically available for the primary manifestations of MPS III.
references:
- reference: PMID:31536183
  title: "Mucopolysaccharidosis Type III."
  tags:
  - GeneReviews
  findings: []
📚

References & Deep Research

References

1
PMID:31536183
Mucopolysaccharidosis Type III.
No top-level findings curated for this source.

Deep Research

1
Sanfilippo syndrome deep research ▸

Sanfilippo syndrome deep research

Date: 2026-04-14

Scope and final framing

  • Target disease: Sanfilippo syndrome / mucopolysaccharidosis type III / MPS III
  • Final root MONDO anchor: MONDO:0018937
  • Final subtype MONDO anchors:
  • MPS IIIA -> MONDO:0009655
  • MPS IIIB -> MONDO:0009656
  • MPS IIIC -> MONDO:0009657
  • MPS IIID -> MONDO:0009658
  • Final subtype gene framing:
  • MPS IIIA -> SGSH / hgnc:10818
  • MPS IIIB -> NAGLU / hgnc:7632
  • MPS IIIC -> HGSNAT / hgnc:26527
  • MPS IIID -> GNS / hgnc:4422

MONDO / Monarch cross-check

I explicitly re-checked the disease anchors rather than trusting the helper note on issue #1312.

Local MONDO check

On 2026-04-14, local OAK/MONDO resolution returned:

  • MONDO:0018937 ! mucopolysaccharidosis type 3
  • MONDO:0009655 ! mucopolysaccharidosis type 3A
  • MONDO:0009656 ! mucopolysaccharidosis type 3B
  • MONDO:0009657 ! mucopolysaccharidosis type 3C
  • MONDO:0009658 ! mucopolysaccharidosis type 3D

Important correction:

  • The issue-helper suggestion that root Sanfilippo syndrome should use MONDO:0001074 was incorrect.
  • On the same 2026-04-14 MONDO check, MONDO:0001074 resolved to chronic tic disorder, not Sanfilippo syndrome.

Why I used the root MONDO term

MONDO:0018937 is the correct umbrella disease anchor for the shared MPS III / Sanfilippo mechanism. The four enzymatic diseases remain represented explicitly as has_subtypes with their own subtype MONDO terms.

ClinGen cross-check

I cross-checked subtype/gene pairing against the local ClinGen gene-validity cache:

  • SGSH -> mucopolysaccharidosis type 3A / MONDO:0009655 -> Definitive
  • assertion date: 2022-06-15
  • NAGLU -> mucopolysaccharidosis type 3B / MONDO:0009656 -> Definitive
  • assertion date: 2022-08-22
  • HGSNAT -> mucopolysaccharidosis type 3C / MONDO:0009657 -> Definitive
  • assertion date: 2023-12-04
  • GNS -> mucopolysaccharidosis type 3D / MONDO:0009658 -> Definitive
  • assertion date: 2022-09-02

Interpretation:

  • ClinGen validity is subtype-specific, not a single root-level one-gene assertion for all of Sanfilippo syndrome.
  • That is exactly the modeling pattern I used in the YAML:
  • one shared disease-level root entry for the convergent mechanism,
  • four subtype records for the etiologic gene split.

Lump vs split reasoning

I intentionally lumped at the Sanfilippo root and split only in the subtype block.

Why this is the right level:

  • All four diseases are defined by failure of sequential lysosomal heparan-sulfate degradation.
  • The dominant shared clinical trajectory is a CNS-predominant neurodegenerative syndrome with developmental regression, behavioral disturbance, sleep problems, and shortened survival.
  • ClinGen still forces subtype-aware gene framing, so the root cannot erase subtype structure.

Why I did not preserve the subtype-A graph as a separate disease-level entry:

  • The merged subtype-A work in PR #1185 is biologically solid, but its proximal node is necessarily SGSH-specific.
  • For a demo-ready root entry, the first mechanism node should be the shared pathway lesion, not one subtype's enzyme.
  • The subtype-A work is therefore best reused as biology to abstract upward, not copied literally.

What I reused from PR #1185

I reused the strongest pieces of the subtype-A curation:

  • the emphasis on lysosomal heparan-sulfate storage as the proximal lesion,
  • the decision to keep neuroinflammation explicit,
  • the treatment logic that enzyme/gene restoration should point back to the storage lesion,
  • the general preference for atomic graph structure.

I changed the granularity in three important ways:

  1. I replaced the SGSH-only upstream node with a shared four-enzyme heparan-sulfate catabolism defect.
  2. I made the middle of the graph shared and conservative:
  3. Lysosomal heparan sulfate accumulation
  4. Neuroinflammatory cascade
  5. Cortical synaptic dysfunction
  6. Progressive central neurodegeneration
  7. I did not keep standalone nodes for autophagy failure, ganglioside storage, or axonal dystrophy because the exact abstract-level support was either weaker, more subtype-limited, or would have made the root graph more brittle for tomorrow's demo.

Final mechanistic graph

The final pathograph is:

  1. Lysosomal heparan sulfate catabolism defect
  2. Lysosomal heparan sulfate accumulation
  3. Neuroinflammatory cascade
  4. Cortical synaptic dysfunction
  5. Progressive central neurodegeneration
  6. Downstream phenotypes and treatment targets

This graph is fully connected and avoids shortcutting:

  • I did not jump directly from the enzyme defect to phenotypes.
  • I did not leave Neuroinflammatory cascade or Cortical synaptic dysfunction dangling.
  • I did not wire storage straight to regression/ID while also claiming the intermediary neuronal dysfunction nodes were important.

Key evidence anchors used in YAML

1. Shared root disease and subtype logic

PMID:25851924

"Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) is a lysosomal storage disorder, caused by a deficiency in one of the four enzymes involved in the catabolism of glycosaminoglycan heparan sulfate."

  • Use: root disease definition and shared upstream mechanism
  • Evidence source in YAML: OTHER
  • Reason: review-level synthesis, not a primary cohort

PMID:31536183

"The diagnosis of MPS III is established in a proband with suggestive clinical and laboratory findings in whom either biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) or deficiency of the respective lysosomal enzyme has been identified."

  • Use: confirm four-gene etiologic split under the root entry
  • Evidence source in YAML: OTHER

2. Shared clinical course

PMID:31536183

"Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration manifest as severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances."

  • Use: progressive central neurodegeneration node plus intellectual disability, developmental regression, and sleep disturbance phenotypes
  • Evidence source in YAML: OTHER

PMID:25851924

"It is characterized by progressive cognitive decline and severe hyperactivity, with relatively mild somatic features."

  • Use: root disease description and Hyperactivity
  • Evidence source in YAML: OTHER

PMID:31536183

"Disease onset is typically before age ten years."

  • Use: progression note for childhood onset
  • Evidence source in YAML: OTHER

PMID:31536183

"Death usually occurs in the second or third decade of life secondary to neurologic regression or respiratory tract infections."

  • Use: progression / shortened survival note
  • Evidence source in YAML: OTHER

3. Shared storage lesion

PMID:36306823

"Enzyme deficiency results in accumulation of partially degraded HS within lysosomes throughout the body, leading to a progressive severe neurological disease."

  • Use: defect -> storage edge and storage node
  • Evidence source in YAML: MODEL_ORGANISM
  • Reason: subtype-A mouse ERT paper, but the quoted biochemical lesion is the same shared proximal consequence expected across the spectrum

4. Storage to inflammation

PMID:37794029

"The lack of functional enzyme in MPS IIIB patients leads to the progressive accumulation of heparan sulfate throughout the body and triggers a cascade of neuroinflammatory and other biochemical processes ultimately resulting in severe mental impairment and early death in adolescence or young adulthood."

  • Use: storage -> neuroinflammatory cascade
  • Also used as partial support for neuroinflammation -> progressive neurodegeneration
  • Evidence source in YAML: MODEL_ORGANISM

5. Storage to neuronal/synaptic dysfunction

PMID:19386237

"Clearance of heparan sulfate oligosaccharides in cultured embryonic MPSIIIB cortical neurons or treatment with proteasome inhibitors restored normal synaptophysin levels indicating that heparan sulfate oligosaccharides activate the degradation of synaptophysin by the proteasome with consequences on synaptic vesicle components that are relevant to clinical manifestations."

  • Use: storage -> cortical synaptic dysfunction
  • Evidence source in YAML: MODEL_ORGANISM

PMID:22558223

"Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary motor, somatosensory and parietal cortex."

  • Use: node-level support for both Neuroinflammatory cascade and Cortical synaptic dysfunction
  • Evidence source in YAML: MODEL_ORGANISM
  • Value: stronger than subtype-A-only evidence because this paper compares IIIA and IIIB

PMID:19386237

"Behavioural manifestations are prominent at disease onset, suggesting possible early synaptic defects in cortical neurons."

  • Use: partial support for the synaptic dysfunction -> hyperactivity link
  • Evidence source in YAML: MODEL_ORGANISM

6. Treatment anchors

PMID:22008915

"In contrast, AAV8-mediated liver-directed gene transfer achieved high and sustained levels of circulating active sulfamidase, which reached normal levels in females and was fourfold higher in males, and completely corrected lysosomal GAG accumulation in most somatic tissues. Remarkably, a 50% reduction of GAG accumulation was achieved throughout the entire brain of males, which correlated with a partial improvement of the pathology of cerebellum and cortex."

  • Use: investigational gene therapy -> inhibition of storage
  • Evidence source in YAML: MODEL_ORGANISM

PMID:21152017

"We report here that high doses of genistein aglycone, given continuously over a 9 month period to MPSIIIB mice, significantly reduce lysosomal storage, heparan sulphate substrate and neuroinflammation in the cerebral cortex and hippocampus, resulting in correction of the behavioural defects observed."

  • Use: substrate reduction therapy -> inhibition of storage and neuroinflammation
  • Evidence source in YAML: MODEL_ORGANISM

PMID:31536183

"Treatment of manifestations: Supportive therapies for neurodevelopmental delays, hearing loss, and visual impairment; medications (rather than behavioral therapy) for psychiatric/behavioral issues; physical therapy and/or orthopedic management of musculoskeletal manifestations; and management as prescribed by consulting specialists for seizures, cardiac involvement, sleep disorders, feeding difficulties."

  • Use: supportive symptomatic care
  • Evidence source in YAML: OTHER

Evidence-source decisions

I was intentionally strict here:

  • PMID:25851924 and PMID:31536183 are review / GeneReviews sources, so I tagged them OTHER, not HUMAN_CLINICAL.
  • PMID:22008915, PMID:21152017, PMID:22558223, PMID:19386237, PMID:36306823, and PMID:37794029 are all preclinical model papers, so I tagged them MODEL_ORGANISM.
  • I did not upgrade review statements to HUMAN_CLINICAL just because they summarize human disease.

Claims I intentionally left out

  • Aggressive behavior as a structured phenotype:
  • true for some subtypes and supported in subtype-A papers,
  • but I did not need it for the root demo once hyperactivity and sleep disturbance were already supported cleanly.
  • Standalone autophagy impairment node:
  • plausible and well-known in the broader Sanfilippo literature,
  • but I did not have abstract-level support strong enough to justify a separate root node without weakening the graph.
  • Standalone ganglioside storage node:
  • present in the literature and seen in PMID:22558223,
  • but I kept it as supporting context inside the synaptic / neuropathology logic rather than adding another node tomorrow's demo does not need.

Final curation decision

  • Build one root disease entry at kb/disorders/Sanfilippo_syndrome.yaml
  • Encode subtype structure in has_subtypes
  • Use the shared HS-storage neurodegenerative pathograph at the root
  • Keep subtype-aware gene framing aligned with ClinGen definitive assertions
  • Prefer a smaller number of strongly connected, exact-quote-supported nodes over a larger but less defensible graph